Skip to main content
Journal cover image

Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.

Publication ,  Journal Article
Pokorney, SD; Mi, X; Hammill, BG; Allen LaPointe, NM; Curtis, LH; Al-Khatib, SM
Published in: Am J Cardiol
May 1, 2017

Ventricular tachycardia (VT) is common in cardiomyopathy patients with an implantable cardioverter-defibrillator. This analysis evaluated antiarrhythmic medication use and change in use over time in patients with VT and structural heart disease. Query of Medicare claims identified patients with an implantable cardioverter-defibrillator and VT. Patients with atrial fibrillation or supraventricular tachycardia were excluded. Two cohorts were created of patients enrolled in Medicare Part D for the 12 months before 2007 and 2012. Patients were identified through a search for antiarrhythmic medication fills with a supply covering January 1 of the cohort year. Adjusted logistic regression modeling evaluated the association between patient characteristics and antiarrhythmic medication use. The 2007 (n = 2,334) and 2012 (n = 3,892) Medicare Part D cohorts had similar demographics: median age 76 years, 64%-67% male, and 87%-89% white. Of the 2007 cohort, 1,380 (59%) patients were on a beta blocker, and 484 (20.7%) were on an antiarrhythmic medication (70% amiodarone and 20% sotalol). Between 2007 and 2012, there was a statistically significant higher use of any antiarrhythmic medication (p = 0.014), beta blockers (p <0.0001), mexiletine (p = 0.005), and ranolazine (p <0.0001), while amiodarone use remained unchanged (p = 0.53). After multivariable adjustment, male gender and renal disease were associated with higher antiarrhythmic medication use. In conclusion, although antiarrhythmic medication and beta blocker use in patients with VT increased over time, <1 in 4 patients were on an antiarrhythmic medication and only 65% of the patients were on a beta blocker.

Duke Scholars

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

May 1, 2017

Volume

119

Issue

9

Start / End Page

1401 / 1406

Location

United States

Related Subject Headings

  • United States
  • Tachycardia, Ventricular
  • Sotalol
  • Sodium Channel Blockers
  • Ranolazine
  • Mexiletine
  • Medicare Part D
  • Male
  • Logistic Models
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pokorney, S. D., Mi, X., Hammill, B. G., Allen LaPointe, N. M., Curtis, L. H., & Al-Khatib, S. M. (2017). Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. Am J Cardiol, 119(9), 1401–1406. https://doi.org/10.1016/j.amjcard.2017.01.030
Pokorney, Sean D., Xiaojuan Mi, Bradley G. Hammill, Nancy M. Allen LaPointe, Lesley H. Curtis, and Sana M. Al-Khatib. “Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.Am J Cardiol 119, no. 9 (May 1, 2017): 1401–6. https://doi.org/10.1016/j.amjcard.2017.01.030.
Pokorney SD, Mi X, Hammill BG, Allen LaPointe NM, Curtis LH, Al-Khatib SM. Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. Am J Cardiol. 2017 May 1;119(9):1401–6.
Pokorney, Sean D., et al. “Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.Am J Cardiol, vol. 119, no. 9, May 2017, pp. 1401–06. Pubmed, doi:10.1016/j.amjcard.2017.01.030.
Pokorney SD, Mi X, Hammill BG, Allen LaPointe NM, Curtis LH, Al-Khatib SM. Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. Am J Cardiol. 2017 May 1;119(9):1401–1406.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

May 1, 2017

Volume

119

Issue

9

Start / End Page

1401 / 1406

Location

United States

Related Subject Headings

  • United States
  • Tachycardia, Ventricular
  • Sotalol
  • Sodium Channel Blockers
  • Ranolazine
  • Mexiletine
  • Medicare Part D
  • Male
  • Logistic Models
  • Humans